Table 1.
Recommended Initial Regimens for Most People With HIV28
| Selection of a regimen for an individual should be guided by factors such as virological efficacy, toxicity, pill burden, dosing frequency, drug–drug interaction potential, resistance testing results, comorbid conditions, access, and cost. | |
|---|---|
| Generic Formulation | Selected Brand-Name Productsd |
| Dolutegravir/abacavir/lamivudinea,b | Fixed-dose combination: Triumeq (ViiV Healthcare) |
| Dolutegravir plus tenofovir/ emtricitabineb,c | Tivicay (ViiV Healthcare) plus Truvada (Gilead Sciences, with TDF) or Descovy (Gilead Sciences, with TAF) |
| Elvitegravir/cobicistat/tenofovir/ emtricitabinec | Fixed-dose combinations: Genvoya (Gilead Sciences, with TAF) or Stribild (Gilead Sciences, with TDF) |
| Raltegravir plus tenofovir/ emtricitabineb,c | Isentress (Merck) plus Truvada (Gilead Sciences, with TDF) or Descovy (Gilead Sciences, with TAF) |
a
Only for patients who are HLA-B*5701-negative
b
Lamivudine may substitute for emtricitabine or vice versa.
c
Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are two forms of tenofo-vir approved by the Food and Drug Administration. TAF has fewer bone and kidney toxicities than TDF, while TDF is associated with lower lipid levels. Safety, cost, and access are among the factors to consider when choosing between these drugs.
d
Individual components of these regimens are available as branded and in some cases generic products.